Characterization of IDH1-mutational status in gliomas by 31P/H1 MRSI

Characterization of IDH1-mutational status in gliomas by 31P/H1 MRSI - 31P and 1H MRSI of brain tumors

Status

Active, not recruiting

Phases

Unknown

Study type

Observational

Source

NL-OMON

Registry ID

NL-OMON43436

Enrollment

Registered

2016-06-16

Start date

2016-02-01

Completion date

Unknown

Last updated

2024-04-23

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

brain tumor glioblastoma glioma

Interventions

None listed

Eligibility

Age

18 Years to 99 Years

Inclusion criteria

Inclusion criteria: Patients must meet all of the following inclusion criteria: - Adult (18+) - Diagnosed low grade or secondary high grade glial brain tumor - MR compatibility is verified using a questionnaire Control group volunteers must meet all of the following inclusion criteria: - Preferably age and sex matched - have no indication of (prior) cerebral abnormalities - MR compatibility is verified using a questionnaire

Exclusion criteria

Exclusion criteria: A potential subject who meets any of the following criteria will be excluded from participation in this study: - unable to provide informed consent - any medical condition is present that might interfere with the study protocol, such as brain injuries, epilepsy, a major cardiovascular disease event or anxiety disorders. - Use of any medication, except for oral contraceptives - MR(I) contraindications (pregnancy, severe claustrophobia, metal parts in body)

Design outcomes

Primary

Measure	Time frame
The main parameters for the 1st objective are the integrated normalized peak areas of GPC and PE (31P MRS) and of 2HG (1H MRS). For the 2nd objective complete spectra will be evaluated. Outcomes will be correlated with IDH status which is available from clinical data.	—

Secondary

Measure	Time frame
n.a.	—

Countries

Netherlands

Outcome results